But why are you comparing two different baseline measurements with each other? I am assuming both baselines were taken on enrollment prior to randomization to one of the two treatment orders (please correct me if I am wrong here). They should be similar (within the known variance of the disease). More proper is to compare either the first or second baseline with the outcome after treatment in my opinion - assuming this is how baselines were collected - I welcome any clarifications here
Ann: Dimerix Plans for Next Study in Diabetic Kidney Disease, page-14
-
- There are more pages in this discussion • 156 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
50.0¢ |
Change
0.050(11.1%) |
Mkt cap ! $277.8M | |||
| Open | High | Low | Value | Volume |
| 46.0¢ | 50.5¢ | 46.0¢ | $1.822M | 3.746M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 38745 | 49.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 50.0¢ | 27099 | 2 |
View Market Depth
| Last trade - 14.35pm 12/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |